Enhanced paclitaxel delivery to tumors using a new lipid nanocapsule-based formulation


2895

M. Gonnet^a, Z. Koob^b, T. Perrier^a, F. Bichat^b, O. Meyer^a, M. Hillairet de Boisferon^b ^a Carlina Technologies, 49100 Angers, France ^b Oncodesign, 21076 Dijon, France

Results

Introduction

TAXOL® (paclitaxel, PTX), one of the first microtubule stabilizing agents, is among the most widely used chemotherapy agents in various cancers, especially ovarian and breast cancer. However, because of its poor water-solubility, PTX must be dissolved in ethanol and Cremophor® EL. Cremophor® EL has been proved to be associated with a number of severe side effects, including hypersensitivity, neurotoxicity and dramatic allereic reactions. These side effects are a major limitation in the use of PTX in the clinic. To avoid these side effects, there is a need to develop alternative formulations of PTX with better aqueous solubility and reduced risk of associated serious adverse effects. In this study, PTX was formulated in Lipid NanoCapsules (LNC), prepared via the phase inversion temperature method. The pharmacokinetics/pharmacodynamic (PK/PD) parameters of PTX-LNC were evaluated in a BALB/C nude mice model bearing human ovarian tumor implanted subcutaneously.



PK experiment Drug administration:

- IV bolus of PTX-LNC and TAXOL® at 20 mg eq PTX/kg


Group	Treatment	Nb animals	Dase (mg/kg/inj)	Adm. Route	Treatment schedule
1	PTX-LNC	3 per timepoints (10 timepoints)	20	IV	QIDx1
2	TAXOL®	3 per timepoints (10 timepoints)	20	IV	Q1Dx1


Tumor induction, randomization and collection

- ✓ SC inoculation of 1x10⁷ SK-OV-3 cancer cells into nude mice Randomization of mice based on tumor volumes (261 ± 42 mm³)
- Collection of tumor, plasma, liver, spleen and kidneys
- Determination of PTX levels in tumor, plasma, liver, spleen and kidneys using HPLC/MS/MS

(1). Principe d'éthique de l'expérimentation animale. Directive n 86/609 CEE du 24 Nov. 1986, Décrêt n 87/848 du 19 Oct. 1987, Arrêté d'Application du 19 Avril 1988

Workman et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102(11):1555-1577.






- A significant MBW loss between D0 and D7 was observed for mice treated with PTX-LNC and TAXOL® at 12 mg/kg when compared to mice treated with NaCl 0.9 % ✓ No significant mean body weight change was observed between PTX-LNC and TAXOL[®] when administered at the same PTX equivalent dose









Similar PTX plasma pharmacokinetic profiles were observed for PTX-LNC and TAXOL® at 20 mg eq PTX/kg in SK-OV-3 tumor bearing mice


Kidney

The PTX half-life of elimination in plasma for PTX-LNC was 2.4 fold shorter than for TAXOL® → The AUC0 083 → 8H was 1.24 fold higher for PTX-LNC compared to

TAXOI @ in tumo


Mean tumor volume curves Mean tumor volume curves of BALB/C nude mice bearing subcutaneous SK-OV-3 tumors.

The mice received one daily IV injection of PTX-LNC or TAXOL® for 5 consecutive days from D0 to D4 (Q1Dx5). The daily treatments are indicated by arrows. Each point represents the mean of the recorded body weight per group (n=12).



Time post random Individual tumor volume curves

A marked and superior inhibition of the tumor growth was observed for mice treated with PTX-LNC when compared to TAXOL® at the same PTX equivalent dose.



Results Treatment effects on the growth of SK-OV-3 tumors subcutaneously xenografted in BALB/C nude mice.

Group	No mice at D0	Mean TGD (days)	SD
1-NaC10,9%, IV: Q1Dx5	12	19.7	6
2-PTX-LNC 12 mg/kg, IV: Q1Dx5	12	54.0***	16
3-TAXOL® 12 mg/kg, IV: Q1Dx5	12	40.2***	8

→ A significant mean time to reach the tumor volume of 600 mm³ difference was observed for mice treated with PTX-LNC and TAXOL® when compared to mice treated with NaCl 0.9 % A significant 1.3 fold-increase of the mean time to reach the tumor volume of 600 mm³ was observed for mice treated with PTX-LNC when compared to mice treated with TAXOL® (54 vs 40 days, respectively)

Summary table of median tumor volume and T/C % calculated by comparing the median tumor volumes of treated mice with the median tumor volume of vehicle treated mice

Group	Parameters	D31
1-NaC10.9%, IV: 01Dx5	Median tumour volume (mm ²)	1064
1-NaC10,9%, IV: Q1D45	TIC %	100
2-PTX-LNC 12 mr/kr, IV: 01Dx5	Median tumour volume (mm ²)	169
2-PTX-ENC 12 mg/kg, IV: Q1D45	T/C %	16
3-TAXOL® 12 mm/kg, IV: 01Dx5	Median tumour volume (mm ²)	307
3-TAXOL-12 lig/ag, iv: QTD45	TIC %	29

At D31, the T/C % values were inferior to effective criteria according to NCI standards and were 16 and 29 % for mice treated with PTX-LNC and TAXOL®, respectively.

Treatment effects on tumor volume of SK-OV-3 tumors subcutaneously xenografted in BALB/C nude mice at D28.

Group	No mice at D0	Mean tumour volume at D28 (mm ²)	SD
1-NaC10,3%, IV: Q1Dx5	12	1018	429
2-PTX-LNC12 mg/kg, IV: Q1Dx5	12	184***	139
3-TAXOL® 12 mp/kg, IV: Q1Dx5	12	286***	181

- A marked and significant decrease of the mean tumor volume at D28 was observed for mice treated with PTY-I NC and TAYOI® when compared to mice treated with NaCl 0.9 % ✓ A slight, but not significant decrease of the mean tumor volume

was observed for the groups of mice treated with PTX-LNC when compared to mice treated with TAXOL® at 12 mg/kg (1.5 fold)

Conclusions

✓ Despite transient BW losses, PTX-LNC was well tolerated by BALB/C nude mice bearing subcutaneous SK-OV-3 tumors.

Hased upon the evaluation criteria of antitumor activity, a marked inhibition of the tumor growth was observed for mice treated with PTX-I NC superior to that observed with TAXOL® at the same PTX equivalent dose

Jimilar PTX pharmacokinetic profiles were observed when treated with PTX-LNC and TAXOL® at equivalent dose in SK-OV-3 tumor bearing mice. However, the exposure of plasma and tumor to PTX after LNC-PTX injection were increased compared to TAXOL®.



